Clinical trials: Endocrine System Disorder
Diabetes
Evaluation of DIDGET TM World Reports
The purpose of this study is to evaluate a Diabetes data management program in the hands of potential users, both lay persons and healthcare professionals.
- Trial name
- NCT00923975
- Testing
- DIDGET World Web Community Reports
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Ascensia Diabetes Care
Diabetes Mellitus, Type 2
A Study of LY900014 in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to compare LY900014 with insulin lispro (Humalog) in participants with type 2 diabetes mellitus. The study will be conducted in participants with type 2 diabetes on insulin injection therapy to…
- Trial name
- NCT03305822
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Diabetes
A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone
This clincial trial is evaluating if the co-administration of saxagliptin and dapagliflozin, in addition to metformin, results in better glycemic control, as measured by HbA1c, over a treatment period of 52 weeks, compared to the…
- Trial name
- NCT02419612
- Testing
- Saxagliptin, Dapagliflozin, Glimepiride
- Where
- 84 sites in United States, Czechia and 8 more
- Volunteers
- 444 people
- Sponsor
- AstraZeneca
Dwarfism, Growth Hormone Deficiency
Drug Use Investigation of Somatropin for GHD-ADULTS.
Post marketing drug use investigation of Genotropin for GHD-ADULTS.
- Trial name
- NCT00601419
- Testing
- Somatropin
- Volunteers
- 230 people
- Sponsor
- Pfizer
Thyroid Carcinoma, Thyroid Cancer
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
The purpose of this study is to develop a new drug treatment to reverse tumor resistance to radioiodine in BRAF mutant tumors so that radioiodine can be given to shrink tumors.
- Conditions
- Thyroid Carcinoma, Thyroid Cancer, Thyroid Cancer, Follicular, Thyroid Cancer (Follicular Cell)
- Trial name
- NCT04462471
- Testing
- I-124 PET/CT lesion dosimetry, Vemurafenib, Copanlisib
- Where
- 7 sites in United States
- Volunteers
- 8 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diabetes Mellitus, Type 2
A Study of LY2599506 in Patients With Type 2 Diabetes
The purpose of this study is to help answer the following questions: To test if taking LY2599506 for 12 weeks controls blood sugar better than taking placebo for 12 weeks.
- Trial name
- NCT01024244
- Testing
- LY2599506
- Where
- 16 sites in United States, Australia and 3 more
- Volunteers
- 78 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
- Trial name
- DEVOTE (NCT01959529)
- Testing
- insulin degludec, insulin glargine
- Where
- 446 sites in United States, Algeria and 18 more
- Volunteers
- 7,637 people
- Sponsor
- Novo Nordisk A/S
Polycystic Ovary Syndrome
Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)
The purpose of this study is to determine if the combination therapy of lifestyle intervention and use of Metformin together will improve ovulation induction and hyperandrogenemia in women with polycystic ovary syndrome, by…
- Trial name
- NCT00151411
- Testing
- Metformin, Lifestyle Intervention
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Secondary Hyperparathyroidism, Chronic Kidney Disease
Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet
The purpose of this study is to demonstrate that treatment with etelcalcetide (AMG 416) is not inferior to treatment with cinacalcet for lowering serum parathyroid hormone (PTH) levels by > 30% from baseline among patients with…
- Trial name
- NCT01896232
- Testing
- Etelcalcetide, Cinacalcet
- Where
- 182 sites in United States, Austria and 20 more
- Volunteers
- 683 people
- Sponsor
- Amgen
Metastatic Pancreatic Cancer
Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas
To evaluate the 6-month overall survival, safety, and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer.
- Trial name
- NCT00837031
- Testing
- Lenalidomide, Gemcitabine
- Where
- 9 sites in United States
- Volunteers
- 72 people
- Sponsor
- SCRI Development Innovations, LLC
Diabetes, Diabetes Mellitus, Type 2
Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects
This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in healthy subjects.
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01473953
- Testing
- liraglutide-depot
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Novo Nordisk A/S
Metastatic Pancreatic Cancer
A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer
This study is designed to determine the duration of T reg suppression in patients with metastatic pancreatic cancer receiving Ontak. The goal is to define the optimal time for future dendritic cell vaccine administration.
- Trial name
- NCT00726037
- Testing
- Ontak
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Loyola University
BRCA1 Gene Mutation, BRCA2 Gene Mutation
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
This phase I/II trial studies the side effects and best dose of olaparib when give together with durvalumab and tremelimumab and to see how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal…
- Conditions
- BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT02953457
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Olaparib
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Roswell Park Cancer Institute
Cushing's Syndrome
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients.
- Trial name
- LINC7 (NCT05633953)
- Testing
- Osilodrostat
- Where
- France
- Volunteers
- 103 people
- Sponsor
- RECORDATI GROUP
NAFLD, Diabetes Mellitus
Improving Detection and Evidence-based Care of NAFLD in Latinx and Black Patients With Type 2 Diabetes
The primary objective of this pilot study is to assess the feasibility and acceptability of an intervention for improved detection and evidence-based care of NAFLD in Latinx and Black patients with type 2 diabetes (T2D) in Duke…
- Trial name
- NAFLD-DM (NCT05844137)
- Testing
- NAFLD Education, diet/lifestyle support, T2D medication management
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University
Diabetes
Performance of a New Glucose Meter System in Children and Young Adults
The purpose of this study is to evaluate the performance of a new blood glucose meter in the hands of children, teens, young adults.
- Trial name
- NCT00985257
- Testing
- DIDGET (Investigational Blood Glucose Monitoring System)
- Where
- 2 sites in United States
- Volunteers
- 123 people
- Sponsor
- Ascensia Diabetes Care
Diabetic Foot
Less Infections for the Diabetic Foot
This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1.
- Trial name
- NCT03615807
- Testing
- Surgical debridement (if needed), Microbiological sampling, Revascularisation (if needed).
- Where
- Switzerland
- Volunteers
- 182 people
- Sponsor
- University Hospital, Geneva
Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Developing Oral LT3 Therapy for Heart Failure - HFpEF
Investigation of the safety, feasibility, and preliminary efficacy of thyroid hormone therapy with Liothyronine (LT3) in individuals with heart failure with preserved ejection fraction (HFpEF) and low triiodothyronine (T3)…
- Trial name
- DOT3HF-HFpEF (NCT04111536)
- Testing
- liothyronine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Diabetes
Advanced Comprehensive Diabetes Care for Veterans With Poorly-Controlled Diabetes
This study will determine whether Home Telehealth-based implementation of an evidence-based intervention targeting Veterans with persistent poorly-controlled diabetes can improve hemoglobin A1c, patient self-management, and…
- Trial name
- ACDC (NCT01778751)
- Testing
- Home Telehealth with Behavioral Education Component
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- VA Office of Research and Development
Diabetes Mellitus, Type 2
Linagliptin 2.5 mg Twice Daily Versus 5 mg Once Daily as add-on Therapy to Twice Daily Metformin in Type 2 Diabetes
The objective of the study is to investigate the efficacy and safety of linagliptin 2.5 mg twice daily compared to 5 mg once daily compared to placebo given orally for 12 weeks as add-on therapy to metformin in patients with type…
- Trial name
- NCT01012037
- Testing
- linagliptin low dose, linagliptin medium dose
- Where
- 84 sites in Belgium, Canada and 7 more
- Volunteers
- 491 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.